Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 18 Breast Neoplasms 16 Lung Neoplasms 10 Carcinoma, Non-Small-Cell Lung 6 Prostatic Neoplasms 5 Melanoma 5 Colorectal Neoplasms 5 Brain Neoplasms 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Skin Neoplasms 3 Myeloproliferative Disorders 3 Leukemia, Myeloid, Acute 3 Kidney Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Hepatocellular 3 Recurrence 2 Neoplasm, Residual 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Lung Diseases 2 Glioma 2 Glioblastoma 2 Genetic Predisposition to Disease 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2

Interventions

spartalizumab 1 pembrolizumab 1 aldesleukin 1 Sunitinib 1 Interleukin-2 1 Blood Specimen Collection 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Kidney Diseases × Blood Specimen Collection × 90 days × Clear all

NCT02822404 2026-04-01

CysPed

University Hospital, Toulouse

Phase NA Completed

Kidney Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡